Ranibizumab: treatment in patients with neovascular age-related macular degeneration
Ranibizumab: treatment in patients with neovascular age-related macular degeneration
复制标题
DOI：
10.1517/14712598.6.11.1237
复制
发表时间：
2006-11-01
影响因子：
4.6
通讯作者：
Avery, Robert L.
中科院分区：
文献类型：
--
作者：
Pieramici, Dante J.;Avery, Robert L.
Vascular endothelial growth factor (VEGF)-A is a major regulator of angiogenesis and vascular permeability implicated in the development of diseases involving pathological angiogenesis and increased vascular permeability, such as neovascular age-related macular degeneration (AMD). LUCENTISTM (ranibizumab), a humanised antigen-binding fragment (Fab) that neutralises all VEGF-A isoforms and their biologically active degradation products, was recently approved by the FDA. Ranibizumab is the first FDA-approved treatment for neovascular AMD that maintains or improves vision in >= 90% patients and provides a >= 15-letter improvement in visual acuity for a quarter to a third of patients with all choroidal neovascularisation subtypes. Ranibizumab was associated with a
